The Evaluation of COVID Medications’ Impact on the Liver Enzymes: A Study on Patients in Al-Ramadi Hospital, Iraq | ||||
| Journal of Bioscience and Applied Research | ||||
| Volume 10, Issue 5, December 2024, Page 57-62 PDF (954.92 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jbaar.2024.391689 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohammed Hashim Mohammed1; Bilal Jasir Mohammed Aldahham   2; Hussein Salim Abed1
| ||||
| 1Department of Medical Laboratory Techniques, Al-Maarif University College, Iraq | ||||
| 2Department of Applied Chemistry, College of Applied Sciences, University of Anbar, Iraq. | ||||
| Abstract | ||||
| This research aims to evaluate the liver enzymes in patients who have recovered from COVID-19 compared to healthy controls. The sample included 69 COVID-19 survivors with liver failure, aged 26 to 66 years (mean age 47.61 ± 11.69). 67 healthy adults aged 19 to 62 years (mean age 36.33) were compared. Pearson correlation (with some differences from Spearman's method) was used to determine the relationship between liver failure and the drugs used during treatment (ceftriaxone, azithromycin, levofloxacin, and remdesivir). The results showed significant differences in ALT, AST, and ALP levels (p<0.001), between the two groups. In recovered patients, ALT is associated with ceftriaxone (R = 0.443, p<0.001) and remdesivir (R = 0.441, p<0.001). AST levels are similarly associated with ceftriaxone (R = 0.529, p<0.001), remdesivir (R = 0.455, p<0.001), and azithromycin (R = 0.366, p<0.001). | ||||
| Keywords | ||||
| Liver enzymes; COVID-19; ceftriaxone; ALT; AST | ||||
|
Statistics Article View: 244 PDF Download: 96 |
||||
